Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...
Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
FierceBiotech8d
Vertex pays Orna $65M to work on next-gen gene therapies for blood disorders
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Billed as nonaddictive, new pain pill could soon win FDA approval
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
kffhealthnews1d
FDA Might Soon Weigh Approval Of Pain Pill To Replace Addictive Opioids
Vertex Pharmaceuticals has a new drug called suzetrigine that it says is nonaddictive and would offer an alternative to painkillers such as oxycodone. The company’s application is pending before the ...
GlobalData on MSN6d
Vertex and Orna sign partnership to improve efficiencies of gene therapies
Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.